Biolase (BIOL)
(Delayed Data from NSDQ)
$0.19 USD
0.00 (-0.68%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $0.18 -0.01 (-5.16%) 4:50 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Biolase, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 49 | 48 | 39 | 23 | 38 |
Cost Of Goods | 32 | 33 | 23 | 17 | 24 |
Gross Profit | 17 | 16 | 17 | 6 | 14 |
Selling & Adminstrative & Depr. & Amort Expenses | 35 | 41 | 33 | 25 | 30 |
Income After Depreciation & Amortization | -18 | -25 | -16 | -19 | -16 |
Non-Operating Income | 0 | 0 | 3 | 4 | -2 |
Interest Expense | 2 | 3 | 2 | 2 | 0 |
Pretax Income | -21 | -29 | -16 | -17 | -18 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -29 | -16 | -17 | -18 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -29 | -16 | -17 | -18 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -24 | -16 | -18 | -14 |
Depreciation & Amortization (Cash Flow) | 3 | 2 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -18 | -25 | -16 | -19 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.28 | 0.07 | 0.06 | 0.02 | 0.01 |
Diluted EPS Before Non-Recurring Items | -29.44 | -416.00 | -325.00 | -1,400.00 | -1,925.00 |
Diluted Net EPS (GAAP) | -29.44 | -416.00 | -275.00 | -1,400.00 | -1,925.00 |
Fiscal Year end for Biolase, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 13.49 | 10.92 | 14.29 | 10.47 | 14.05 |
Cost Of Goods | 9.97 | 7.18 | 8.17 | 7.13 | 10.46 |
Gross Profit | 3.52 | 3.75 | 6.12 | 3.34 | 3.60 |
SG&A, R&D, and Dept/Amort Expenses | 8.60 | 7.44 | 9.99 | 8.63 | 12.02 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.08 | -3.69 | -3.87 | -5.29 | -8.42 |
Non-Operating Income | 0.34 | -0.28 | -0.38 | 0.02 | 0.11 |
Interest Expense | 0.60 | 0.60 | 0.58 | 0.58 | 1.46 |
Pretax Income | -5.34 | -4.57 | -4.84 | -5.85 | -9.77 |
Income Taxes | -0.02 | 0.02 | 0.03 | 0.00 | 0.09 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.33 | -4.59 | -4.87 | -5.85 | -9.86 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.33 | -4.59 | -4.87 | -5.85 | -9.86 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 3.03 | 1.18 | 0.55 | 0.33 | 0.08 |
Diluted EPS Before Non-Recurring Items | -1.76 | -3.89 | -8.93 | -18.00 | -128.00 |
Diluted Net EPS (GAAP) | 1.38 | -3.89 | -8.93 | -18.00 | -134.00 |